China Biopharmaceuticals Holdings, Inc
www.cbioinc.com Press Release
- --------------------------------------------------------------------------------
FOR IMMEDIATE RELEASE: CONTACT:
Chris Peng Mao, CEO
86-10-85251616
info@cbioinc.com
Brian Rafferty
212-889-4350
brian.rafferty@taylor-rafferty.com
China Biopharmaceuticals Applies on American Stock Exchange
BEIJING, China, August 3, 2006 -- China Biopharmaceuticals Holdings, Inc. (OTC
BB: CHBP), a leading Chinese pharmaceutical company focused on the development,
manufacturing and distribution of innovative drugs in China, announced today
that it has submitted application for listing its common stock on the American
Stock Exchange ("AMEX"). The application is pending approval by AMEX.
Chris Peng Mao, CHBP CEO, stated, "Our application to list on the AMEX
represents a further step in our journey to build CHBP into one of China's
leading pharmaceutical companies. If approved, the move will not only help raise
CHBP's visibility in the US market, but will improve the stock liquidity and
tradability as we strive to broaden and deepen the market for our shares."
"Thus far, 2006 has proven to be a transformative year for CHBP from both a
tactical and strategic standpoint. Through the successful acquisition of
complementary operating subsidiaries and our continued focus on innovative drug
development, CHBP has made significant advances in its core operating areas
including the research, development, manufacturing and marketing of leading
drugs and drug raw materials. These recent developments, along with our intended
listing on the AMEX, further demonstrate our focus on strategic goals and our
commitment to building shareholder value."
About China Biopharmaceuticals Holdings
China Biopharmaceutical Holdings, Inc (CBH) is a research driven pharmaceutical
company dedicated to the discovery, development, manufacturing and marketing of
small and large molecule pharmaceutical products, including medicines, vaccines,
and active pharmaceutical ingredients for various categories of diseases.
CBH is a US public company with operating subsidiaries and senior management
based in China.
For further information, please visit our website at www.cbioinc.com.
Safe Harbor Statement
The statements contained herein that are not historical facts are "forward
looking statements" within the meaning of Section 21E of the Securities and
Exchange Act of 1934, as amended, and the Private Securities Litigation Reform
Act of 1995. Such forward-looking statements may be identified by, among other
things, the use of forward-looking terminology such as "believes," "expects,"
"may," "will," "should," or "anticipates" or the negative thereof or other
variations thereon or comparable terminology, or by discussions of strategy that
involve risks and uncertainties. In particular, our statements regarding the
potential growth of the markets are examples of such forward-looking statements.
The forward-looking statements include risks and uncertainties, including but
not limited to, general economic conditions and regulatory developments, not
within our control. The factors discussed herein and expressed from time to time
in our filings with the Securities and Exchange Commission could cause actual
results and developments to be materially different from those expressed or
implied by such statements. The forward looking statements are made only as of
the date of this filing, and we undertake no obligation to publicly update such
forward-looking statements to reflect subsequent events or circumstances.
###